Advertisement
UK markets close in 1 hour 8 minutes
  • FTSE 100

    7,866.15
    -10.90 (-0.14%)
     
  • FTSE 250

    19,350.72
    -99.95 (-0.51%)
     
  • AIM

    743.87
    -1.42 (-0.19%)
     
  • GBP/EUR

    1.1672
    -0.0011 (-0.10%)
     
  • GBP/USD

    1.2452
    +0.0013 (+0.11%)
     
  • Bitcoin GBP

    51,864.80
    +783.16 (+1.53%)
     
  • CMC Crypto 200

    1,380.65
    +68.02 (+5.47%)
     
  • S&P 500

    4,999.04
    -12.08 (-0.24%)
     
  • DOW

    37,921.46
    +146.08 (+0.39%)
     
  • CRUDE OIL

    82.90
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,398.70
    +0.70 (+0.03%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,762.16
    -75.24 (-0.42%)
     
  • CAC 40

    8,037.36
    +14.10 (+0.18%)
     

A Look at Novo Nordisk’s Biopharmaceuticals

A Look at Novo Nordisk’s Biopharmaceuticals

In the first quarter, Novo Nordisk’s (NVO) Hemophilia segment generated net revenues of 2.5 billion Danish kroner compared to 2.58 billion Danish kroner in the first quarter of 2017, reflecting ~3.0% YoY (year-over-year) growth.